Skip to main content
POOLBEG PHARMA PLC logo

POOLBEG PHARMA PLC — Investor Relations & Filings

Ticker · POLB ISIN · GB00BKPG7Z60 LEI · 213800UZ8WJLWYHBFL52 IL Manufacturing
Open in API
Filings indexed 160 across all filing types
Latest filing 2022-10-21 Report Publication Anno…
Country GB United Kingdom
Listing IL POLB

About POOLBEG PHARMA PLC

https://poolbegpharma.com/

Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company that develops and commercializes medicines for diseases with high unmet medical needs. The company's lead asset, POLB 001, is a treatment designed to prevent Cytokine Release Syndrome (CRS), a severe side effect associated with cancer immunotherapies, with the aim of making these treatments safer and more accessible. Poolbeg is also advancing an oral GLP-1 program for obesity, offering a patient-friendly therapeutic option. The company utilizes an artificial intelligence (AI)-led discovery platform that analyzes data from human challenge trials to identify novel drug targets. This AI-driven approach aims to accelerate target identification, reduce costs, and lower development risks.

Recent filings

Filing Released Lang Actions
Upcoming events participation
Report Publication Announcement Classification · 1% confidence The document is an announcement from Poolbeg Pharma PLC, identified by the RNS Number and the date (21 October 2022). The content details the company's management and business development team attending and presenting at several upcoming partnering and investor events (BIO-Europe, Jefferies London Healthcare Conference, JP Morgan Conference, etc.) between October 2022 and January 2023. This type of communication, which lists future investor engagement activities rather than releasing financial results, board changes, or regulatory outcomes, is best classified as general investor relations information. Since it is not a specific financial report (like 10-K or IR), a management discussion (MDA), or a presentation document (IP), and it is a formal announcement distributed via RNS, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate update, or potentially Investor Presentation (IP) if it were the presentation itself. Given the structure—announcing attendance at future events—RNS is the most appropriate general classification for this type of corporate activity update distributed through the regulatory news service.
2022-10-21 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1935 characters) and contains the header 'RNS Number : 0801C'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement that doesn't fit the specific categories like DIRS, DIV, or DLST, the most appropriate fallback category is Regulatory Filings (RNS).
2022-10-06 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1918 characters) and announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange. It explicitly states that the information is provided by 'RNS, the news service of the London Stock Exchange' and is approved by the Financial Conduct Authority (FCA). This structure—a brief, time-sensitive announcement disseminated via the official regulatory news service (RNS)—fits the definition of a general regulatory filing or announcement that doesn't correspond to a specific financial report type (like 10-K, ER, or IR). Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-10-06 English
CEO Share Purchase
Director's Dealing Classification · 1% confidence The document is a regulatory announcement disseminated via RNS (RNS Number : 9515B) from Poolbeg Pharma PLC, dated October 6, 2022. The core content details a 'CEO Share Purchase' by Jeremy Skillington, including the number of shares purchased and the price. The structure, including the 'Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs")' section and references to MAR (Market Abuse Regulations), strongly indicates an insider transaction report. This specific type of filing, reporting personal share transactions by directors, corresponds directly to the 'Director's Dealing' category (DIRS). Although it is distributed via RNS, the specific nature of the content overrides the general fallback.
2022-10-06 English
POLB 001 US Patent update
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 6380B' and contains standard boilerplate language at the end referencing 'RNS, the news service of the London Stock Exchange' and the FCA. The content provides an update on the company's intellectual property (IP) portfolio, specifically regarding a US patent application for POLB 001 being allowed. This is a specific corporate announcement related to assets and strategy, not a full financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). Since it is a formal, non-financial regulatory announcement distributed via the RNS system that doesn't fit into the more specific categories like DIRS, DVA, or CAP, the most appropriate classification is the general regulatory announcement category, RNS.
2022-10-04 English
Poolbeg licence of Melioidosis vaccine candidate
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number' and contains standard regulatory boilerplate language at the end, including a reference to the Financial Conduct Authority (FCA) and RNS (Regulatory News Service). The content announces a specific corporate action: Poolbeg Pharma completing the in-licence of a Melioidosis vaccine candidate (POLB 003) from University College Dublin (UCD). This is a material corporate event announcement, not a full financial report (like 10-K or IR), a transcript (CT), or a presentation (IP). Since it is a formal announcement distributed via the RNS system, and it details a specific business development (licensing/acquisition of an asset), it fits best under the general 'Regulatory Filings' category (RNS) as a primary news release, although it could also be considered a Capital/Financing Update (CAP) if the focus was purely on the deal structure, but RNS is the most accurate classification for a standard RNS distribution notice.
2022-09-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.